Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


Virus or bacteriophage

Subclass of:

424 - Drug, bio-affecting and body treating compositions

424930100 - WHOLE LIVE MICRO-ORGANISM, CELL, OR VIRUS CONTAINING

Patent class list (only not empty are listed)

Deeper subclasses:

Entries
DocumentTitleDate
20110177037Solenopsis invicta Virus07-21-2011
20080260698Chimeric sindbis-western equine encephalitis virus and uses thereof - The present invention discloses a chimeric alphavirus comprising a Sindbis virus cDNA fragment, an Eastern equine encephalitis virus cDNA fragment, a Western equine encephalitis virus cDNA fragment or a combination thereof. The present also discloses the use of this chimeric alphavirus as vaccines and in serological and diagnostic assays.10-23-2008
20080260697Bacterial Management in Animal Holding Systems - The present invention is directed to method for reducing a population of a target pathogen in an animal or within a feedlot. The method involves administering one or more than one controlled release bacteriophage strain or phage component, or both, to the animal, so that the one, or more than one bacteriophage strain is released in vivo and adsorbs to the one or more than one target pathogen, thereby reducing the one, or more than one pathogen from the animal. The controlled release bacteriophage strain or phage component may be administered as a treatment dose prior to further processing of the animal, a treatment dose followed by a maintenance dose, or a maintenance dose, to manage feedlot target pathogens.10-23-2008
20110195052BONE MATRIX COMPOSITIONS AND METHODS - The present invention provides methods of improving the osteogenic and/or chondrogenic activity of a bone matrix, e.g., a dermineralized bone matrix (DBM), by exposing the bone matrix to one or more treatments or conditions. In preferred embodiments the bone matrix is derived from human bone. The treatment or condition may alter the structure of the bone matrix and/or cleave one or more specific proteins. Cleavage may generate peptides or protein fragments that have osteoinductive, osteogenic, or chondrogenic activity. Preferred treatments include collagenase and various other proteases. The invention further provides improved bone and cartilage matrix compositions that have been prepared according to the inventive methods and methods of treatment using the compositions. The invention further provides methods of preparing, testing, and using the improved bone matrix compositions. On a assay comprises exposing relatively undifferentiated mesenchymal cells to a bone matrix composition and measuring expression of a marker characteristic of osteoblast or chondrocyte lineage(s). Increased expression of the marker relative to the level of the marker in cells that have been exposed to a control matrix (e.g., an inactivated or untreated matrix) indicates that the treatment or condition increased the osteogenic and/or chondrogenic activity of the bone matrix. Suitable cells include C2C12 cells. A suitable marker is alkaline phosphatase. The inventive methods increase the osteogenic and/or chondrogenic activity of human DBM when tested using this assay system.08-11-2011
20110195053Treatment of Non-Neuronal Cancer using HSV-1 Variants - A mutant herpes simplex virus which has been modified in the γ34.5 gene such that the gene is non-functional is used to treat a non-neuronal cancer such as a mesothelioma, ovarian carcinoma, bladder cancer or melanoma. Typically, the mutant herpes simplex virus has been modified within the BamHI restriction fragment of the long terminal repeat of the viral genome.08-11-2011
20100158869COMPOSITIONS, DEVICES AND METHODS FOR TREATMENT OF HUNTINGTON'S DISEASE THROUGH INTRACRANIAL DELIVERY OF SIRNA - The present invention provides devices, small interfering RNAs, and methods for treating a neurodegenerative disorder comprising the steps of surgically implanting a catheter so that a discharge portion of the catheter lies adjacent to a predetermined infusion site in a brain, and discharging through the discharge portion of the catheter a predetermined dosage of at least one substance capable of inhibiting production of at least one neurodegenerative protein. The present invention also provides valuable small interfering RNA vectors, systems, and methods for treating Huntington's disease in vivo without impairment of cell endoplasmic reticulum, spontaneous motor activity, or locomotor activity of a patient.06-24-2010
20120244127AAV Vectors Expressing SEC10 for Treating Kidney Damage - A method for enhancing repair of damaged mammalian tubular epithelial cells involves delivering to the tubular epithelial cells of a subject in need thereof a composition comprising an adeno-associated virus (AAV) comprising an AAV capsid having an amino acid sequence of a selected AAV serotype, and a minigene having AAV inverted terminal repeats and a Sec10 gene operatively linked to regulatory sequences that direct expression of Sec10 in the epithelial cells. In one embodiment, delivery is accomplished by retrograde intrauretal injection. In an embodiment the AAV vector includes a capsid of AAV serotype 2/8. Therapeutic compositions containing such AAV are provided.09-27-2012
20120244126ENGINEERED ENZYMATICALLY ACTIVE BACTERIOPHAGE AND METHODS FOR DISPERSING BIOFILMS - The present invention is directed to engineered enzymatically active bacteriophages that are both capable of killing the bacteria by lysis and dispersing the bacterial biofilm because they have been also engineered to express biofilm-degrading enzymes, particularly dispersin B (DspB), an enzyme that hydrolyzes β-1,6-N-acetyl-D-glucosamine, a crucial adhesion molecule needed for biofilm formation and integrity in 09-27-2012
20120183508GAMMA SECRETASE INHIBITOR FOR TREATMENT OF HERPESVIRUS INFECTION - This invention relates to methods and compositions for the treatment of malignancies associated with gamma-herpesvirus infection. Specifically, the invention s relates to the use of gamma-secretase inhibitors to prevent the production of intracellular Notch1 thereby arresting the growth of the infected cells.07-19-2012
20100034777Method for Regulating Protein Function in Cells In Vivo Using Synthetic Small Molecules - Methods and compositions for the rapid and reversible destabilizing of specific proteins in vivo using cell-permeable, synthetic molecules are described.02-11-2010
20130039891POXVIRAL ONCOLYTIC VECTORS - The present invention relates to a poxvirus comprising a defective F4L and/or I4L gene, to composition comprising such poxvirus and to the methods and use of such compositions and poxviruses for therapeutic purposes, and more particularly for the treatment of cancer.02-14-2013
20100104537Methods of treating Parkinson's disease using viral vectors - Methods of delivering viral vectors, particularly recombinant AAV virions, to the CNS are provided. Also provided are methods of treating Parkinson's Disease.04-29-2010
20100104538BENEFICIAL EFFECTS OF BACTERIOPHAGE TREATMENTS - The invention relates to use of one or more bacteriophages in vivoin a human or animal in order to induce sensitivity to chemical antibiotics in bacterial cells, where such susceptibility is heritable, independent of continuing bacteriophage metabolism within those cells, and does not relate to the destruction of a biofilm to induce such sensitivity.04-29-2010
20090155217Novel E. coli O157:H7 Bacteriophage and Uses Thereof - The present invention is directed to isolated bacteriophage having strong lytic activity against strains of 06-18-2009
20090214479ATTENUATED REOVIRUS - Compositions and methods are provided that relate to an attenuated reovirus exhibiting oncolytic activity toward cancer cells while displaying reduced lytic activity toward non-malignant cells. Exemplified is an attenuated human reovirus derived from persistently infected fibrosarcoma cells that lacks wild-type reovirus S1 and S4 genes and consequently lacks a detectable reoviral outer capsid σ1 protein and expresses a mutated reoviral outer capsid σ3 protein.08-27-2009
20130045186Method of Detecting and/or Identifying Adeno-Associated Virus (AAV) Sequences and Isolating Novel Sequences Identified Thereby - Adeno-associated virus rh.10 sequences, vectors containing same, and methods of use are provided.02-21-2013
20100143308AKT NUCLEIC ACIDS, POLYPEPTIDES, AND USES THEREOF - The present invention relates to human Akt3 proteins and polypeptides. The invention also relates to isolated nucleic acids encoding human Akt3, to vectors containing them and to their therapeutic uses, in particular for gene therapy. Expression of Akt3 inhibits cell death associated with hypoxia, apoptosis or necrosis.06-10-2010
20100143309VIRAL VECTORS - The present invention provides a herpes virus which lacks a functional ICP34.5 encoding gene and which comprises two or more of—(i) a gene encoding a prodrug converting enzyme; (ii) a gene encoding a protein capable of causing cell to cell fusion; and (iii) a gene encoding an immunomodulatory protein.06-10-2010
20130089525ANTIMICROBIAL COMPOSITIONS AND METHODS OF USE THEREOF - The present application discloses a method for treating microbial infection using an antimicrobial composition comprises antimicrobial peptide which contains at least one VGFPV motif.04-11-2013
20130052165Methods of Producing Adenovirus Vectors and Viral Preparations Generated Thereby - The present invention, in some embodiments thereof, relates to methods of producing adenoviruses such as pro- and anti-angiogenic adenovirus vectors and preparations generated thereby. Particularly, in some embodiments, the viral vectors comprise a heterologous pro- or anti-angiogenic gene under the transcriptional control of the murine pre-proendothelin promoter (e.g. PPE-1-3X), for targeted expression of in angiogenic endothelium.02-28-2013
20090304638Composition for the treatment of ballast water containing bacteriophage as an effective component and biological method with the same for removing bacteria present in ballast water - The present invention relates to a composition for the treatment of ballast water containing bacteriophage capable of killing specific target bacteria as an active ingredient in order to eliminate or reduce bacteria including pathogenic bacteria present in ballast water, and a biological treatment method of ballast water.12-10-2009
20130058899Cancer Therapy with a Parvovirus Combined with an HDAC Inhibitor - Described is a pharmaceutical composition comprising (a) a parvovirus and (b) a histone deacetylase inhibitor (HDACI) and the use of said composition for treatment of cancer, e.g., brain tumor, cervical carcinoma, or pancreatic carcinoma.03-07-2013
20110014157METHOD FOR PRODUCING A MIXTURE OF BACTERIOPHAGES AND THE USE THEREOF IN THE THERAPY OF ANTIBIOTIC-RESISTANT STAPHYLOCOCCI - The invention relates to a method for producing a mixture of bacteriophages, wherein at least two different bacteriophage strains have been reproduced separately, wherein a 01-20-2011
20090238797NICOTINE-CARRIER VACCINE FORMULATION - The present invention is in the fields of medicine, public health, vaccine and drug formulation. The invention provides composition formulations comprising a nicotine-carrier conjugate and a stabilizer, wherein said stabilizer comprises a non-reducing disaccharide and a non-ionic surfactant. The composition formulations are stable after a long time of storage at room temperature.09-24-2009
20100086522DISPARATE SUICIDE CARRIER CELLS FOR TUMOR TARGETING OF PROMISCUOUS ONCOLYTIC VIRUSES - The invention provides compositions and methods for treating neoplastic disease, such as cancer, with an oncolytic virus, such as VSV. A carrier cell is used to target a diseased tissue, and to cloak the oncolytic virus from surveillance by the subject's immune system during a targeting interval. Following delivery of the virus to the target tissue, the lysis of the carrier cell, and of the target cell, by the oncolytic virus, promotes an adaptive tumouricidal immune response. A wide variety of disparate carrier cells may be used, in conjunction with a promiscuous oncolytic virus having broad tropism, in an approach which facilitates successive treatments in which a new carrier will not be susceptible to an adaptive immune response mounted against previously used carriers. The promiscuity of the virus also facilitates lysis of carrier cells and target cells that are allogenic or xenogenic. The lytic phase of the carrier cell infection is staged so that the carrier is administered in an eclipse phase, and lysis follows the conclusion of the therapeutic targeting interval.04-08-2010
20090191158DEFECTIVE INTERFERING VIRUS - Cloned, i.e. defined, defective interfering (DI) influenza A virus is produced in embryonated hens eggs using a method which generates large quantities of DI virus material. Cloned DI virus is then used in tests on mice and ferrets given a lethal challenge of wild-type influenza A virus. When cloned DI influenza A virus is co-administered with a lethal dose of virulent influenza A virus, mice are protected compared to a control of inactivated cloned DI influenza A virus. Mice which survived the administration of cloned DI influenza A virus and infective challenge virus are three weeks later still protected against lethal challenge with infective virus. Control mice which received only cloned DI influenza A virus and no lethal challenge are not protected three weeks later on lethal challenge with infective virus.07-30-2009
20130164264DEFECTIVE INTERFERING VIRUS - Cloned, i.e. defined, defective interfering (DI) influenza A virus is produced in embryonated hens eggs using a method which generates large quantities of DI virus material. Co-administration of cloned DI influenza A virus with a lethal dose of virulent influenza A virus conferred protection in mice compared to a control of inactivated cloned DI influenza A virus. Control mice which received only cloned DI influenza A virus and no lethal challenge of virulent influenza A virus were not protected three weeks later on lethal challenge with infective virus. Cloned DI influenza A virus of one subtype is found to act in vivo as an effective antiviral against the same or any other sub-type of influenza A virus. The antiviral effect has been found to have both a therapeutic and a prophylactic application against influenza A infection in humans, mammals and birds.06-27-2013
20100291041BACTERIOPHAGE PREPARATION AND USE - The invention relates to a bacteriophage preparation having at least one bacteriophage in alkaline buffer solution, said bacteriophage being specifically effective against at least one bacterial strain, in combination with at least one surface-active agent that is preferably a polyhexamethyl biguanide (polyhexanide) stabilized in an alkaline range between pH 7.5 and pH 9.0. The invention further relates to the use of such a bacteriophage preparation for the production of a pharmaceutical, particularly for therapeutic, preventative, and disinfecting antibacterial use. Finally, the invention also relates to a disinfection method using the bacteriophage preparation together with low-frequency ultrasound.11-18-2010
20110286972VIRUS GROWING IN HYPOXIC CELL OR VIRUS VECTOR EXPRESSING GENE THEREIN - The present invention provides a virus or a viral vector capable of expressing a gene specifically in a cell having replication ability in a hypoxic state such as a cancer stem cell and injuring the cell, and pharmaceutical composition comprising the same. Specifically, the present invention provides a virus or a viral vector which comprises a gene encoding a fusion protein of an ODD and a protein essentially required for viral proliferation, and a pharmaceutical composition comprising the same.11-24-2011
20110293571METHOD FOR VECTOR DELIVERY - Provided is a lentiviral vector for delivery to the brain for use in treating a neurological condition, wherein the lentiviral vector is delivered directly to the brain by delivering the lentiviral vector via six or fewer tracts per hemisphere, at a single deposit point per tract.12-01-2011
20090180992COMPOSITIONS AND METHODS FOR THE TREATMENT, MITIGATION AND REMEDIATION OF BIOCORROSION - A method of reducing biocorrosion or biofilm blockage in by identifying a target suspected of comprising one or more biocorrosive organisms and delivering to the target suspected of comprising the biocorrosive organisms an effective amount of a composition comprising an infective virulent viral panel sufficient to reduce the amount of biocorrosive organisms at the target.07-16-2009
20090130063PROCESS FOR SEPARATING AND DETERMINING THE VIRAL LOAD IN A PANCREATIN SAMPLE - Processes for separating a viral load from a pancreatin sample and for quantitatively determining the viral load in a pancreatin sample with high sensitivity are described herein.05-21-2009
20100266551ADENO-ASSOCIATED VIRAL VECTORS FOR THE EXPRESSION OF DYSFERLIN - The present invention relates to a composition comprising: a first adeno-associated viral (AAV) vector comprising: i) a 5′ITR (Inverted Terminal Repeat) sequence of AAV; ii) a portion of gene placed under the control of a promoter; iii) a sequence comprising a splice donor site; iv) a 3′ITR sequence of AAV; and/or a second adeno-associated viral (AAV) vector comprising; v) a 5′ITR (Inverted Terminal Repeat) sequence of AAV; vi) a sequence comprising a splice acceptor site; vii) a portion of gene; viii) a 3′ITR sequence of AAV. The combination of the portions of gene carried by the first and second AAV vectors comprises an open reading frame which encodes a functional dysferlin. In addition, the combination of the sequence comprising the splice donor site and the sequence comprising the splice acceptor site contains all the elements necessary for the splicing, advantageously derived from a natural intron of the dysferlin gene.10-21-2010
20090297484METHOD FOR CURING AND PREVENTING ACQUIRED IMMUNE DEFICIENCY SYNDROME BY ALTERING CELL-SURFACE RECEPTORS IN PRECURSOR T-HELPER CELLS AND MATURE T-HELPER CELLS TO PREVENT HUMAN IMMUNODEFICIENCY VIRUS VIRIONS ACCESS TO MATURE HELPER CELLS - The medical method by which a modified Human Immunodeficiency Virus or virus-like structure is used as a transport medium to carry a medically therapeutic ribonucleic acid to precursor T-Helper cells and mature T-Helper cells to prevent AIDS. The modified Human Immunodeficiency Virus or virus-like structures make contact with precursor T-Helper cells or mature T-Helper cells by means exterior probes. Once the exterior probes engage the precursor T-Helper cells' or mature T-Helper cells' cell-surface receptors, the modified virus or virus-like structures inserts into the cells the medically therapeutic ribonucleic acid they are carrying. The medically therapeutic ribonucleic acid causes T-Helper cells to express an altered cell-surface receptor on their surface thus thwarting HIV virions from being able to gain access to such cells, thus preventing AIDS.12-03-2009
20100080776METHOD OF ENHANCING AN IMMUNE RESPONSE - A method of enhancing an immune response to an antigen is provided. The method involves augmenting the level of a TAP molecule in a target cell bearing the antigen. Preferably, the TAP molecules enhanced by administering a nucleic acid sequence encoding a TAP-1 and/or TAP-2 molecule. The method is useful in treating infectious diseases and cancer.04-01-2010
20090169519MEDICINAL FORMULATION CONTAINING A COMBINATION OF HIV TYPE I AND HIV TYPE II - A novel medicinal formulation for the treatment of autoimmune diseases, said formulation comprising, combined serially diluted and potentized HIV TYPE I virus and HIV TYPE II virus, said dilution being effected in a vehicle selected from a group consisting of distilled water or ethyl alcohol and mixture of distilled water and ethyl alcohol.07-02-2009
20100092431Edwardsiella Ictaluri Bacteriophage and Uses Thereof - Disclosed are isolated bacteriophage that have lytic activity for species of 04-15-2010
20110033425Parvovirus Having a CPG-Enriched Genome Useful for Cancer Therapy - A parvovirus characterized by a CpG-enriched genome, wherein the genome contains at least 2 additional CpG inserts that are not present in the wild type genome is described as well as the use of said parvovirus, e.g., a parvovirus based on parvovirus H1, LuIII, Mouse minute virus (MMV), Mouse parvovirus (MPV), Rat minute virus (RMV), Rat parvovirus (RPV), Rat virus (RV), vectors based on the foregoing viral species, and/or cells capable of actively producing the foregoing viral species for the preparation of a pharmaceutical composition, e.g., for the treatment of cancer, preferably pancreas carcinoma, hepatoma or lymphoma.02-10-2011
20090010894METHODS AND SYSTEMS FOR IDENTIFYING COMPOUNDS THAT MODULATE ALPHA-SYNUCLEIN AGGREGATION - This invention relates to the field of determining the ability of agents to interfere with, reverse, or prevent α-synuclein aggregation and α-synuclein-related pathology and behavior. This invention also relates to methods for screening candidate agents for their potential as human medicaments.01-08-2009
20080206202METHODS FOR APPLICATION OF ENDOGENOUS OR EXOGENOUS STEM/PROGENITOR OR THEIR PROGENY FOR TREATMENT OF DISEASE - We propose here that endogenous stem/progenitor cells of the developing or adult nervous system be genetically modified in situ, to express therapeutically advantageous gene products. Furthermore, we propose here that endogenous or other exogenous stem cells or their progeny be genetically modified when appropriate to express advantageous gene products (and/or modified through culture techniques), and that, if exogenously derived, they be transplanted into the ventricular system of the patient nervous system, the germinal zone of the ventricular system, into postmitotic regions of the CNS or other organs.08-28-2008
20090291063COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL HEPATITIS - The present invention discloses a novel apathogenic viral strain useful in the treatment of viral hepatitis infections. The preferred viral strain of Infectious Bursal Disease Virus (IBDV) is specifically characterized in terms of structure and biological activities. The invention also provides recombinant IBDV viral vectors for the inclusion of exogenous nucleic acid sequences enhancing the viral replication inhibitory effect of the virus of the invention. Preferably, the viral vector comprises a nucleic acid sequence encoding a cytokine. A method of treating viral hepatitis in a host comprising administering an anti-hepatitis effective amount of the IBDV strain of the present invention also provided.11-26-2009
20100284975POLYPEPTIDES COMPRISING FAS ACTIVATION AND NKG2D-LIGAND DOMAINS - The present invention is drawn to fusion proteins comprising (a) a ligand for an NK receptor and (b) a Fas activation domain, and to nucleic acids encoding such fusion proteins. The invention also includes methods of making and using such proteins and nucleic acids, including their use in preventing or treating cancer.11-11-2010
20090297483Adenovirus vectors specific for cells expressing androgen receptor and methods of use thereof - Replication-competent adenovirus vectors specific for cells which allow a probasin transcriptional response element (PB-TRE) to function, such as cells which express the androgen receptor (AR), and methods of use of such viruses are provided. These viruses comprise an adenoviral gene under control of a transcriptional regulatory portion of a PB-TRE, which is in turn dependent upon AR expression. The gene can be, for example, a gene required for viral replication or the adenovirus death protein gene (ADP). The viruses can also comprise at least one additional adenoviral gene under control of at least one additional prostate-specific transcriptional response element, such as that controlling prostate-specific antigen expression (PSA-TRE). Thus, virus replication can be restricted to target cells exhibiting prostate-specific gene expression, particularly prostate carcinoma cells. An adenovirus of the present invention can further comprise a heterologous gene such as a reporter under transcriptional control of a PB-TRE. The adenovirus vectors can be used to detect and monitor samples for the presence of prostate cells as well as to selectively kill malignant cells producing prostate-specific gene products.12-03-2009
20100129325SENECA VALLEY VIRUS BASED COMPOSITIONS AND METHODS FOR TREATING DISEASE - The present invention relates to a novel RNA picornavirus that is called Seneca Valley virus (“SVV”). The invention provides isolated SVV nucleic acids and proteins encoded by these nucleic acids. Further, the invention provides antibodies that are raised against the SVV proteins. Because SVV has the ability to selectively kill some types of tumors, the invention provides methods of using SVV and SVV polypeptides to treat cancer. Because SVV specifically targets certain tumors, the invention provides methods of using SVV nucleic acids and proteins to detect cancer. Additionally, due to the information provided by the tumor-specific mechanisms of SVV, the invention provides methods of making new oncolytic virus derivatives and of altering viruses to have tumor-specific tropisms.05-27-2010
20080311082Process for Treating Animal Waste - The present invention is directed to a process for reducing a population of one, or more than one target pathogen present in animal waste, including livestock manure , comprising administering one, or more than one protected bacteriophage strain to livestock. The one, or more than one bateriophage strain is capable of adsorbing to and killing the target pathogen, is released in vivo, and acts to clear the one or more than one pathogen from livestock gut and waste. The one, or more than one bacteriophage it further reduces the population of the one or more than one target pathogen in the waste or manure. The present invention also relates to a process for reducing a population of one, or more than one target pathogen present in liquid manure comprising treating the animal waste such as liquid manure with one, or more than one protected bateriophage strain, or phage components, or a combination thereof.12-18-2008
20080267920MONOPARAMUNITY INDUCERS BASED ON ATTENUATED RABBIT MYXOMAVIRUSES - The present invention relates to monoparamunity inducers based on paramunizing viruses or viral components of a myxomavirus strain from rabbits with typically generalizing disease, to a method for the production thereof and to the use thereof as medicaments for the regulatory optimization of the paramunizing activities for the prophylaxis and therapy of various dysfunctions in humans and animals.10-30-2008
20100135962Novel Bacteriophage and Antibacterial Composition Comprising the Same - The present invention relates to a novel bacteriophage, more particularly, a bacteriophage that has a specific bactericidal activity against Fowl Typhoid causing 06-03-2010
20110268705HDAC4, HDAC5, HDAC6, HDAC7, AND HIF1 ALPHA MODULATION OF RETINAL CELL SURVIVAL - Methods for inhibiting retinal cell death by altering expression of one or more of HDAC4, HDAC5, HDAC6, HDAC7, and HIF1α in a retinal cell are provided.11-03-2011
20120141427Attenuated Strain of Myxoma Virus for Use as an Oncolytic Drug - The invention relates to the use of an attenuated vaccinal strain of 06-07-2012
20120141426Reovirus for the Treatment of Cellular Proliferative Disorders - Methods for treating proliferative disorders, by administering reovirus to a Ras-mediated proliferative disorder, are disclosed. The reovirus is administered so that it ultimately directly contacts ras-mediated proliferating cells. Proliferative disorders include but are not limited to neoplasms. Human reovirus, non-human mammalian reovirus, and/or avian reovirus can be used. If the reovirus is human reovirus, serotype 1 (e.g., strain Lang), serotype 2 (e.g., strain Jones), serotype 3 (e.g., strain Dearing or strain Abney), as well as other serotypes or strains of reovirus can be used. Combinations of more than one type and/or strain of reovirus can be used, as can reovirus from different species of animal. Either solid neoplasms or hematopoietic neoplasms can be treated.06-07-2012
20120141424Materials and Methods for the Treatment of Hypertension - The present invention is directed to materials and methods for the treatment of hypertension and ischemia comprising administering at least one therapeutic agent selected from the group consisting of vascular endothelial growth factor-C product and vascular endothelial growth factor-D product, and optionally, when treating hypertension, a standard of care anti-hypertensive agent.06-07-2012
20090324553Chimeric Viral Envelopes - The invention relates to chimeric polytropic viral envelope polypeptides and uses thereof, as well as to polynucleotides encoding said chimeric polypeptides and constructs comprising said polypeptides and/or polynucleotides. The invention also relates to chimeric retroviral envelope polypeptides, polynucleotides and vectors encoding said chimeric retroviral envelope polypeptides, virus particles and cells harbouring said chimeric envelope polypeptides. Said chimeric polypeptide comprise an envelope polypeptide, or fragment thereof, and a polypeptide sequence of a receptor binding region, ligand or polypeptide sequence of a ligand binding region, and optionally a linker sequence. The invention include methods of targeting receptors, methods of treatment and methods for delivery of agents using said chimeric retroviral envelope polypeptides. The invention is applicable for directed targeting and controlled fusion of virus particles with other cellular membranes.12-31-2009
20090053179METHOD FOR USING LIBERATED DORMANT BACTERIOPHAGE AND ENVIRONMENTAL STRESS TO REDUCE INFECTIOUS BACTERIA - A method for obtaining bacteriophages by stressing bacteria. The method involves isolating bacteria, propagating the bacteria, exposing the bacteria to at least one environmental stressing agent to induce excision of bacteriophage that are present in the bacterial genome. Multiple or individual environmental stressing agents may be applied. These liberated bacteriophages may be collected for purposes of treating pathogenic infections, protecting plants and agricultural products or general sterilization and sanitation.02-26-2009
20110142803METHOD FOR TREATING INFLAMMATION ASSOCIATED WITH AMYLOID DEPOSITS AND BRAIN INFLAMMATION INVOLVING ACTIVATED MICROGLIA - Filamentous bacteriophage which does not display an antibody or a non-filamentous bacteriophage antigen on its surface is used to inhibit or treat brain inflammation associated with amyloid deposits and/or involving activated microglia, to inhibit the formation of amyloid deposits, and to disaggregate pre-formed amyloid deposits.06-16-2011
20090098089REOVIRUS FOR THE TREATMENT OF NEOPLASIA - Methods for treating neoplasia, by administering reovirus to a Ras-mediated neoplasm, are disclosed. The reovirus is administered so that it ultimately directly contacts cells of the neoplasm. Human reovirus, non-human mammalian reovirus, and/or avian reovirus can be used. If the reovirus is human reovirus, type 1 (e.g., strain Lang), type 2 (e.g., strain Jones), type 3 (e.g., strain Dearing or strain Abney), as well as other serotypes or strains of reovirus can be used. Combinations of more than one type and/or strain of reovirus can be used, as can reovirus from different species of animal. Either solid neoplasms or hematopoietic neoplasms can be treated.04-16-2009
20100297085Synthetic Herpes Simplex Viruses Type-1 for Treatment of Cancers - A recombinant herpes simplex virus type-1 (HSV-1) has been constructed that carries a deletion of one of the two viral γ11-25-2010
20090004149METHOD FOR LIMITING THE GROWTH OF CANCER CELLS USING AN ATTENUATED MEASLES VIRUS - A method for treating cancer cells is provided comprising directly or systemically administering a therapeutically effective dose of an attenuated measles virus. In one embodiment, the therapeutically effective dose is from about 1001-01-2009
20090220460VIRUS STRAINS - The present invention relates to clinical herpes simplex virus (HSV) isolates with improved oncolytic capabilities as compared to reference laboratory HSV strains. The present invention also relates to methods of producing HSV strains of the invention and to pharmaceutical compositions comprising a HSV strain of the invention.09-03-2009
20100040580FREEZE-DRIED COMPOSITION OF INACTIVATED VIRUS ENVELOPE WITH MEMBRANE FUSION ACTIVITY - The objects of the present invention are to provide a freeze-dried composition of an inactivated virus envelop having membrane fusion activity which can be stored at higher temperatures without losing the ability to introduce foreign matters and to provide a method of introducing a foreign matter into a cell with high efficiency.02-18-2010
20100003220AGENTS FOR TREATING MALIGNANT MESOTHELIOMA - The present invention provides an effective therapeutic composition for malignant mesothelioma. Specifically, the present invention provides a therapeutic composition for mesothelioma, comprising a calponin-targeting and tumor-lysing variant of herpes simplex virus (HSV-1), preferably a strain d12.CALPfΔRR. The present invention further provides a method for generating a cell for treating mesothelioma, which comprises infecting mesothelioma cells removed from a patient with an F-type variant of herpes simplex virus proliferating with targeting a calponin gene, preferably a strain d12.CALPfΔRR. Also provided are a cell obtainable by the method, and a calponin-targeting and tumor-lysing variant of herpes simplex virus (HSV-1), preferably a strain d12.CALPfΔRR.01-07-2010
20090117082Reovirus for the Treatment of Cellular Proliferative Disorders - Methods for treating proliferative disorders, by administering reovirus to a Ras-mediated proliferative disorder, are disclosed. The reovirus is administered so that it ultimately directly contacts ras-mediated proliferating cells. Proliferative disorders include but are not limited to neoplasms. Human reovirus, non-human mammalian reovirus, and/or avian reovirus can be used. If the reovirus is human reovirus, serotype 1 (e.g., strain Lang), serotype 2 (e.g., strain Jones), serotype 3 (e.g., strain Dearing or strain Abney), as well as other serotypes or strains of reovirus can be used. Combinations of more than one type and/or strain of reovirus can be used, as can reovirus from different species of animal. Either solid neoplasms or hematopoietic neoplasms can be treated.05-07-2009
20090117081PARVOVIRUS METHODS AND COMPOSITIONS FOR KILLING NEOPLASTIC CELLS - According to the invention, parvoviruses such as the adeno-associated virus Type 2 (AAV2) are found to be oncolytic, selectively mediating apoptosis in cancer cells and their precursers, while leaving healthy cells intact. The invention thus comprises a method of killing cancer and other neoplastic and preneoplastic cells by administration of AAV2 virus, viral particles, products or replication incompetent vectors derived there from to said cells, and pharmaceutical compositions comprising the same.05-07-2009
20110110896Modulating levels of RNA-binding proteins for the treatment of breast cancer - The present invention relates to methods of using RNA-binding protein modulating agents to treat of cancer, particularly patients that are susceptible to or diagnosed with estrogen receptor-negative breast cancer, such as methods of inhibiting the growth or metastasis of cancer cells comprising contacting cells with a therapeutically-effective amount of an HuR-modulating agent. The invention also relates to compositions comprising therapeutically-effective amounts of an HuR-modulating agent.05-12-2011
20100015098ISOLATED PHAGES AND THEIR USE IN FOOD OR PET FOOD PRODUCTS - The present invention relates to phage isolates having a strong lytic activity against pathogenic Enterobacteriaceae such as 01-21-2010
20110059049POXVIRAL ONCOLYTIC VECTORS - A poxvirus other than NYVAC but comprising a defective F4L and/or I4L gene and compositions comprising such poxvirus are useful for therapeutic purposes, and more particularly for the treatment of cancer.03-10-2011
20120141425VIRUS-LIKE PARTICLE VECTOR FOR DELIVERY OF PHARMACEUTICAL AGENTS, A PROCESS FOR THE MANUFACTURE THEREOF, ITS USES AND A PHARMACEUTICAL COMPOSITION - The embodiment of the invention is a virus-like particle vector, a process for the manufacture thereof, use of the virus-like particle vector and a pharmaceutical composition, which contains the virus-like particle vector. The vector is intended for the delivery of therapeutic agents into specific mammalian tissues, especially low molecular weight agents, in particular low molecular weight anti-cancer drugs into cancer tissues. More specifically, the invention relates to the virus-like particle vector, which constitutes an adenoviral dodecahedron with the therapeutic substance encapsulated or covalently linked.06-07-2012
20100098668Oncolytic Adenoviruses and Uses Thereof - The disclosed subject matter provides methods and materials relating to viral vectors, such as adenoviral vectors, that effectively target cancer cells and that express a protein that specifically binds to Transforming Growth Factor-β.04-22-2010
20100221228y134.5 Deficient HSV and the MAPK Pathway - The invention provides materials and methods for the identification of cells exhibiting a cell proliferative disorder that are amenable to treatment with a herpes simplex virus that does not express an approximately wild-type level of ICP34.5. Also provided are methods of treating cell proliferative diseases, disorders or conditions, such as cancers, rheumatoid arthritis and macular degeneration, using these HSVs. Further provided are methods for preventing such cell proliferative disorders by administering the HSVs as well as methods for ameliorating a symptom associated with a cell proliferative disorder by administering such HSVs.09-02-2010
20090232770PROCESS OF PRODUCTION OF BACTERIOPHAGE COMPOSITIONS AND METHODS IN PHAGE THERAPY FIELD - A method for producing bacteriophage stock compositions including (a) incubating a culture medium including at least one bacterial strain, at least one bacteriophage strain that can infect the bacterial strain, and at least one antibiotic, wherein the concentration of the antibiotic in the medium is in a range which causes about 0.1% to about 99.9% inhibition of the growth of the bacterial strain in the absence of the bacteriophage strain; (b) continuing incubation of the culture medium until bacterial lysis occurs, thereby obtaining a bacteriophage lysate; and preparing a crude bacteriophage extract from the culture medium.09-17-2009
20090074726MVA EXPRESSING MODIFIED HIV ENVELOPE, GAG, AND POL GENES - The invention provides modified virus Ankara (MVA), a replication-deficient strain of vaccinia virus, expressing human immunodeficiency virus (HIV) env, gag, and pol genes.03-19-2009
20090110665REOVIRUS FOR THE TREATMENT OF NEOPLASIA - Methods for treating neoplasia, by administering reovirus to a Ras-mediated neoplasm, are disclosed. The reovirus is administered so that it ultimately directly contacts cells of the neoplasm. Human reovirus, non-human mammalian reovirus, and/or avian reovirus can be used. If the reovirus is human reovirus, type 1 (e.g., strain Lang), type 2 (e.g., strain Jones), type 3 (e.g., strain Dearing or strain Abney), as well as other serotypes or strains of reovirus can be used. Combinations of more than one type and/or strain of reovirus can be used, as can reovirus from different species of animal. Either solid neoplasms or hematopoietic neoplasms can be treated.04-30-2009
20100291040VIRUS-LIKE PARTICLES FOR TREATMENT OF VIRAL INFECTIONS - The invention provides virus-like particles for treatment of viral infections based on the virus causing the infection. The virus-like particles comprise the virus recombinant proteins that form a capsid, recombinant virus membrane proteins attached to the capsid and vRNA packaged within said capsid. The vRNA is generated from a DNA sequence encoding a polypeptide capable of specifically binding to a constant region of a nonstructural protein of the virus that is essential for propagation of the virus.11-18-2010
20100297086Bacteriophage preparations and methods of use thereof - Disclosed herein are purified bacteriophage preparations that effectively lyse a plurality of 11-25-2010
20110117060CANCER TREATMENT USING VIRUSES, FLUOROPYRIMIDINES AND CAMPTOTHECINS - Mammalian subjects having a neoplasm are treated with a virus, a fluoropyrimidine, for example 5-fluorouracil, and a camptothecin compound. The virus is selected from the group consisting of a Newcastle disease virus, a measles virus, a vesicular stomatitis virus, an influenza virus, a Sindbis virus, a picornavirus, and a myxoma virus.05-19-2011
20080206201Recombinant Newcastle Disease Virus - The goal of the invention is to increase the therapeutical activity of oncolytic NDV. This issue is solved by a Newcastle Disease Virus comprising a recombinant nucleic acid, wherein the nucleic acid codes for a binding protein that has a therapeutic activity when expressed by the virus-infected tumor cell. Binding proteins belong to the following group: A natural ligand or a genetically modified ligand, a recombinant soluble domain of a natural receptor or a modified version of it, a peptide-ligand, an antibody molecule and derivatives thereof or antibody-like molecules like ankyrin repeat molecules or derivatives thereof.08-28-2008
20110243897MODIFICATION OF NUCLEIC ACID VECTORS WITH POLYMERS COMPRISING CHARGED QUATERNARY AMINO GROUPS - The present invention provides a polymer modified nucleic acid vector in which the nucleic acid vector is covalently linked to a polymer, which polymer comprises one or more positively charged quaternary amino groups.10-06-2011
20110008295SIMIAN ADENOVIRUSES SADV-36, -42.1, -42.2, AND -44 AND USES THEREOF - A recombinant vector comprises simian adenovirus 36, simian adenovirus 42.1, simian adenovirus 42.2 and/or simian adenovirus 44 sequences and a heterologous gene under the control of regulatory sequences. A cell line which expresses one or more simian adenovirus-36, -42.1, -42.2 or -44 gene(s) is also described. Methods of using the vectors and cell lines are provided.01-13-2011
20110008293DEVICE AND METHOD FOR PREPARING MICROPARTICLES - The invention provides a method for preparing microparticles comprising mixing a first cross-linkable reagent in aerosol form with a second cross-linking reagent in aerosol form to thereby to form microparticles.01-13-2011
20110033424USE OF ADENOVIRUS AND NUCLEIC ACIDS CODING THEREFOR - The invention relates to the use of a virus, preferably an adenovirus, for producing a medicament. Said virus is replication-deficient in cells which do not contain YB-1 in the core and codes for an oncogene or oncogene product, especially an oncogene protein, which transactivates at least one viral gene, preferably an adenoviral gene, said gene being selected among the group comprising E1B55kDa, E4orf6, E4orf3, and E3ADP.02-10-2011
20100330041Viral-based antimicrobial agent use in ethanol production - A process of controlling unwanted microorganism contamination in the fermentation of mash to form ethanol, particularly to control 12-30-2010
20110020288Reoviruses Having Modified Sequences - The invention provides for modified reovirus nucleic acid sequences and modified reovirus polypeptide sequences as well as reoviruses containing such modified nucleic acid or polypeptide sequences. The invention also provides for pharmaceutical compositions that include reoviruses having a modified sequence as well as methods of making and using such reoviruses.01-27-2011
20110052542NOVEL BACTERIOPHAGE AND ANTIBACTERIAL COMPOSITION COMPRISING THE SAME - Disclosed herein is a novel bacteriophage which has specific bactericidal activity against one or more 03-03-2011
20110129446Clone of newcastle disease virus, its manufacture and its application in the medical treatment of cancer - A new clone of Newcastle disease virus which is interferon insensitive and has an ICPI between 1.2 and 2.0 and which may be used in the treatment of cancer and other diseases.06-02-2011
20090028828Rotavirus Vaccine Inducing Heterotypic Cross Protection - The invention provides a method of inducing an immune response against rotavirus strain, the method comprising administering to a subject a composition comprising an attenuated rotavirus strain of a GxPy type, said composition generating an immune response against a rotavirus strain which is neither a Gx nor a Py type.01-29-2009
20110070200ABROGATING PROINFLAMMATORY CYTOKINE PRODUCTION DURING ONCOLYTIC REOVIRUS THERAPY - Provided herein are methods for treating a proliferative disorder in a subject comprising administering to the subject one or more reoviruses and one or more agents that modulate expression or activity of pro-inflammatory cytokines. For example, the agents may inhibit expression or activity of pro-inflammatory cytokines.03-24-2011
20100310521POLYNUCLEOTIDE SEQUENCE FOR THE INHIBITION OF PHOSPHOLAMBAN SYNTHESIS - A DNA polynucleotide sequence is disclosed that comprises a transcribed sequence, and a promoter sequence. Transcription of the transcribed sequence by an RNA polymerase in a cell renders an RNA a transcript capable of forming a partially self-complementary hairpin structure which can be processed by the cell to an siRNA product that can degrade phospholamban mRNA in such cell. The promoter is a drug inducible conditional promoter or a cardiomyocyte cell-specific promoter or both, operably linked to the transcribed sequence. The promoter is operable by an RNA polymerase naturally occurring in a mammalian cell.12-09-2010
20100310522Novel Polypeptides Having Endolysin Activity and Uses Thereof - The present invention provides isolated polypeptides comprising the amino acid sequence of SEQ ID NO:1, or a fragment, variant, derivative or fusion thereof which is capable of binding specifically to and/or lysing cells of 12-09-2010
20080247997EXTERNAL ANIMAL LAYER SANITATION USING BACTERIOPHAGE - Methods for disinfecting external layers from animals include applying phage to the external layers. Phage may be applied before an external layer is removed from a remainder of an animal's body, during the removal process, or following removal of the external layer from the remainder of the animal's body.10-09-2008
20090324554METHOD FOR INHIBITING OR TREATING A DISEASE ASSOCIATED WITH INTRACELLULAR FORMATION OF PROTEIN FIBRILLAR OR AGGREGATES - A therapeutic agent which carries a peptide sequence containing a mammalian cell adhesion sequence can be used to inhibit or treat diseases associated with intracellular formation of protein fibrillar inclusions or aggregates, to inhibit the intracellular formation of protein fibrillar inclusions or aggregates, and to disaggregate pre-formed intracellular protein fibrillar inclusions or aggregates. Filamentous bacteriophage which displays a non-filamentous bacteriophage RGD cell adhesion sequence on its surface, but not an antibody or non-filamentous bacteriophage antigen other than said RGD cell adhesion sequence, is a preferred embodiment of such a therapeutic agent.12-31-2009
20110020287Parvovirus Cancer Therapy and Combination with Chemotherapy - Described is a pharmaceutical composition containing (a) a parvovirus and (b) a chemotherapeutic agent, preferably as separate entities. The parvovirus might be based on parvovirus H1, LuIII, Mouse minute virus (MMV), Mouse parvovirus (MPV), Rat minute virus (RMV), Rat parvovirus (RPV), Rat virus (RV), vectors based on the foregoing viral species, and/or cells capable of actively producing the foregoing viral species. The pharmaceutical composition is beneficial for the treatment of a tumor. Tumors for which a parvovirus or the adjunction of the invention has particular utility include glioma, medulloblastoma, meningioma and pancreatic cancer. Preferred chemotherapeutic agents are gemcitabine and Temozolodine.01-27-2011
20110020289NOVEL MYCOVIRUS, ATTENUATED STRAIN OF PHYTOPATHOGENIC FUNGUS, PLANT DISEASE CONTROLLING AGENT, METHOD OF PRODUCING MYCOVIRUS, METHOD OF ATTENUATING PHYTOPATHOGENIC FUNGUS AND METHOD OF CONTROLLING PLANT DISEASE - The present invention provides a novel mycovirus that suppresses phytopathogenic fungi and a novel method for controlling plant diseases. A novel mycovirus that is present endogenously in a predetermined rice blast fungus, has four types of double-stranded RNAs of 2.8 to 3.6 kb, and suppresses a phytopathogenic fungus has been found. This virus suppresses phytopathogenic fungi such as rice blast fungus.01-27-2011
20110020290BACTERIOPHAGE-CONTAINING THERAPEUTIC AGENTS - The present invention relates in its broadest aspect to combined phage/antibiotic therapy. More particularly, it relates to use of (i) one or more bacteriophages and (ii) one or more antibiotics in the manufacture of a combined product for simultaneous, separate or sequential administration of (i) and (ii) to treat a bacterial infection characterized by biofilm formation, for example an infection comprising or consisting of 01-27-2011
20100284974VIRAL CAPSID PROTEINS AND ANY PEPTIDES OR COMPOSITIONS THEREOF FOR THE TREATMENT OF PATHOLOGIC DISORDERS - The present invention relates to viral capsid proteins, as a medicament for the treatment of a pathologic disorder. More particularly, the invention relates to the viral capsid proteins VP1, VP2 and VP3, preferably, the SV40 VP1 or any peptide, fragment, mutant, derivative and mixtures thereof or of virus-like particles (VLP's) comprising the same, as the active ingredient in compositions for the treatment of pathologic disorders, preferably disorders associated with inactivation of cellular proteins involved with quality control processes, particularly, chaperones. The invention further provides methods for the treatment of such disorders and the use of the SV40 capsid proteins for the preparation of pharmaceutical compositions.11-11-2010
20110064699REDUCING CONJUGATIVE PLASMIDS IN BACTERIA - The present invention provides methods and compositions to reduce prevalence of plasmids in microbial colonies, including infections, and includes therapeutic compositions, methods for treatment of infections, and methods for identifying additional such compositions. Means are provided to reduce the copy numbers of antibiotic resistance genes, and to confer phage binding to cells lacking receptors for those phage.03-17-2011
20110256104COMPLEXING AGENTS FOR COMPOSITIONS CONTAINING INCLUSION COMPLEXES - The invention provides a composition containing particulate composite of a polymer and a therapeutic agent. The composition also contains a complexing agent. The polymer interacts with the complexing agent in a host-guest or a guest-host interaction to form an inclusion complex. A therapeutic composition of the invention may be used to deliver the therapeutic agent and to treat various disorders. Both the polymer of the particulate composite and the complexing agent may be used to introduce functionality into the therapeutic composition. The invention also relates to a method of preparing a composition. The method combines a therapeutic agent, a polymer having host or guest functionality, and a complexing agent having guest or host functionality to form the therapeutic composition. The complexing agent forms an inclusion complex with the polymer. The invention also relates to a method of delivering a therapeutic agent. According to the method, a therapeutically effective amount of a therapeutic composition of the invention is administered to a mammal (e.g. person or animal) in recognized need of the therapeutic. Also disclosed are compounds having the formula:10-20-2011
20110052544NOVEL BACTERIOPHAGE AND ANTIBACTERIAL COMPOSITION COMPRISING THE SAME - Disclosed herein are is a novel bacteriophage which has specific bactericidal activity against one or more 03-03-2011
20110052543NOVEL BACTERIOPHAGE AND ANTIBACTERIAL COMPOSITION COMPRISING THE SAME - Disclosed herein are is a novel bacteriophage which has specific bactericidal activity against one or more 03-03-2011
20110052541NOVEL BACTERIOPHAGE AND ANTIBACTERIAL COMPOSITION COMPRISING THE SAME - Disclosed herein are is a novel bacteriophage which has specific bactericidal activity against one or more 03-03-2011
20110052540Non-Aggregating Virus Formulation - The present invention is a composition comprising a virus, a polyol and a zwitteronic compound. The present invention is also an assay for viral aggregation, which comprises analysing the size of the viral particles in a sample, wherein the particles are in admixture with a polyol, and determining from the size whether the sample contains substantially only acceptable, non-aggregated particles.03-03-2011
20110052539ONCOLYTIC RHABDOVIRUS - Embodiments of the invention include compositions and methods related to non-VSV rhabdoviruses and their use as anti-cancer therapeutics. Such rhabdoviruses possess tumor cell killing properties in vitro and in vivo.03-03-2011
20100254950Bacteriophage or lytic protein derived from the bacteriophage which effective for the treatment of staphylococcus aureus biofilm - The present invention relates to compositions for removing a biofilm formed by 10-07-2010
20100322905Compositions and methods for treating pancreatic cancer - The present invention provides a method of treating pancreatic cancer by inhibiting the activity cyclin D1 activity in tumor cells. The invention is based on the finding that cyclin D1 shRNA molecules are capable of attenuating tumor growth and interfering with tumor angiogenesis.12-23-2010
20110256103 METHOD OF PRODUCING A PHARMACOLOGICALLY STABLE FORM OF LYOPHILISED, ACTIVE PREPARATIONS OF PURIFIED BACTERIOPHAGES - The subject the present invention is a method of producing a pharmacologically stable form of purified and lyophilised bacteriophage preparations of increased stability and antibacterial activity, characterised in that phages produced from a bacterial lysate, for example by ultrafiltration on ultrafiltration membranes, containing a high molecular weight preparation of purified phages is stabilised most preferably with a probiotic extract in the presence or absence of neutral salts and/or organic solvents, lyophilised, characterised via HPLC chromatography, by SDS-PAGE, and bacterial lysis biological assays, and then stored under a vacuum, where the active lyophilisate is destined for phage therapy of infections and tumours.10-20-2011
20100166709Novel Bacteriophage and Antibacterial Composition Comprising the Same - The present invention relates to a novel bacteriophage, more particularly, a bacteriophage that has a specific bactericidal activity against one or more 07-01-2010
20100158871Sickled erythrocytes with antitumor molecules induce tumoricidal effects - The present invention provides erythrocytes or nucleated erythrocyte precursors from animals or patients with at least one S hemoglobin allele which are capable of selectively localizing in tumor vasculature resulting in vaso-occlusion, hemolysis and heme release. A tumoricidal effect is achieved when these cells are administered in before during or after administration of (i) an agent(s) that interferes with degradation of reactive oxygen species, (ii) impairs glucose uptake and/or (iii) chemotherapy. These cells also carry oncolytic viruses, antitumor proteins, multidrug resistant proteins, chemotherapy, monoclonal antibodies, superantigens, superantigen conjugates and fusion proteins, siRNAs, plasmids and non-protein toxins and attenuated tumoricidal bacterial cells specifically into the tumors and induce a tumoricidal effect.06-24-2010
20100158870NOVEL BACTERIOPHAGE AND ANTIBACTERIAL COMPOSITION COMPRISING THE SAME - The present invention relates to a novel bacteriophage, more particularly, a bacteriophage that has a specific bactericidal activity against 06-24-2010
20100196324MULTIFUNCTIONAL CYTOKINES - The present invention relates to a novel fusion protein with the formula X-Y, or Y-X, wherein X represents a first immunoregulating polypeptide and Y represents a second immunoregulating polypeptide different from X. The present invention also relates to a nucleic acid molecule encoding such a fusion protein and a vector comprising such a nucleic acid molecule. The present invention also provides infectious viral particles and host cells comprising such a nucleic acid molecule or such a vector as well as a process for producing such infectious viral particles. The present invention also relates to a method for recombinantly producing such a fusion protein. Finally, the present invention also provides a pharmaceutical composition comprising such a fusion protein, a nucleic acid molecule, a vector, infectious viral particles and a host cell as well as the therapeutic use thereof.08-05-2010
20100003221Medium Supplement for Virus Production - The use of macrolide polyene antibiotics or derivatives or analogues thereof as culture supplement for the propagation of virus is described. Further pharmaceutical compositions comprising a virus and a macrolide polyene antibiotic or a derivative or analogue thereof and methods for using of macrolide polyene antibiotics for transfection and infection of cells as well as the use of macrolide poylene antibiotics for the isolation of virus from clinical samples are disclosed.01-07-2010
20090175831ADAPTABLE MESSENGER RIBONUCLEIC ACID MEDICAL TREATMENT DEVICE TO MANAGE DIABETES MELLITUS - Diabetes mellitus is a disease of elevated blood glucose, often directly related to a deficiency in insulin production or insulin receptor production. The innovative strategy of treatment described here utilizes modified viruses to act as a transport vehicle to deliver to target cells in the body, messenger RNA molecules. Delivering to the beta cells in the body the messenger RNA molecules needed to construct insulin or insulin receptors will lead to enhanced production of biologically active insulin or insulin receptors by beta cells as necessary, which will lead to correcting deficiencies in insulin or insulin receptors the result of which will help properly regulate blood glucose levels throughout the body utilizing innate regulatory mechanisms.07-09-2009
20100021431Agent for Promoting the Production of Thioredoxin - A novel pharmaceutical application of an extract from a vaccine virus-inoculated and inflamed tissue and relates to a thioredoxin production promoting agent containing the extract as an active ingredient. The extract has an excellent thioredoxin production promoting action against an oxidative stress caused by a stimulus by such as a tobacco smoke extract or hydrogen peroxide and showed a significant lung cell protective effect. Therefore, the pharmaceutical of the invention containing the extract as an active ingredient is highly useful as a preventive or therapeutic agent for a chronic obstructive lung disease considered to be mainly caused by a continuous oxidative stress such as chronic smoking and the pharmaceutical with less side effects and high safety.01-28-2010
20100021432Sensitization of Chemotherapeutic Agent Resistant Neoplastic Cells with a Virus - The present invention relates to a method of increasing the sensitivity of neoplastic cells to chemotherapeutic agents by using a virus, a method of treating proliferative disorders with a virus and chemotherapeutic agents, and a method for preventing a neoplasm from developing drug resistance to chemotherapeutic agents. The virus is preferably a reovirus.01-28-2010
20090104157UTILIZATION OF BACTERIOPHAGE TO CONTROL BACTERIAL CONTAMINATION IN FERMENTATION PROCESSES - A fermentation process for the production of ethanol from natural sources, such as corn, comprising introducing a fermentable sugar and an inoculant, and a bacteriophage cocktail into a fermentation system and introducing a cocktail comprising one or more lytic bacteriophage is added to one or more of the fermentable sugar, the inoculant, or the fermentation system. Bacteriophages that infect and lyse the bacteria that contaminate fermentable sugars are selected. The bacteriophage cocktail is added in an amount effective to substantially prevent growth of these bacteria.04-23-2009
20100129326PURIFICATION OF VACCINIA VIRUS- AND RECOMBINANT VACCINIA VIRUS-BASED VACCINES - The present invention relates to methods for purification of Vaccinia viruses (W) and/or Vaccinia virus (W) particles, which can lead to highly pure and stable virus preparations of predominantly biologically active viruses. The invention encompasses purifying a virus preparation in a sterilized way with high efficiency and desirable yield in terms of purity, biological activity and stability, aspects advantageous for industrial production.05-27-2010
20100196325Use of modified vaccinia virus strains in combination with a chemotherapeutic agent for use in therapeutic methods - Modified or attenuated therapeutic viruses in combination with a chemotherapeutic agent, and methods for administering therapeutic viruses in combination with a chemotherapeutic agent to a subject for controlling viral titer, are provided. The combination of a therapeutic virus and chemotherapeutic agent can be used in methods of treating diseases, such as proliferative and inflammatory disorders, including as anti-tumor agents. The combination can also be used as a preventive measure or as a treatment to reduce or eliminate symptoms associated with oncolytic viral therapy.08-05-2010
20110318311TUMOR-SELECTIVE E1A AND E1B MUTANTS - Modified E1a regulatory sequences are provided, wherein at least one Pea3 binding site, or a functional portion thereof, is deleted. Also provided are modified E1a sequences that selectively express particular isoforms. Also provided is an E1b-19K clone insertion site. These modified sequences can be used individually, or in combination with one another, to provide tumor-selective expression of proteins.12-29-2011
20090047255Alphavirus and Alphavirus Replicon Particle Formulations and Methods - Disclosed are methods for preparing dried (preferably lyophilized) preparations comprising a population of alphaviruses or alphavirus replicon particles, a sugar or polyol, a surfactant and a salt and preparations made by said methods, both in the dried form but also as liquids prior to drying or after reconstituting dried preparations. These preparations may further comprise a plasticizer and/or a bulking agent. These preparations are readily reconstituted, with little or no loss in infectivity of the viruses or replicon particles.02-19-2009
20120114612Oncolytic Viruses And Methods For Treating Neoplastic Disorders - The disclosure provides mutant ribonucleotide reductase strains of poxviruses including for example vaccinia viruses. The disclosure also provides methods and for the use of these mutant ribonucleotide reductase strains of vaccinia viruses in oncolytic virotherapy.05-10-2012
20120114611BACTERIOPHAGE-CONTAINING THERAPEUTIC AGENTS - The present invention relates in its broadest aspect to combined phage/antibiotic therapy. More particularly, it relates to use of (i) one or more bacteriophages and (ii) one or more antibiotics in the manufacture of a combined product for simultaneous, separate or sequential administration of (i) and (ii) to treat a bacterial infection characterized by biofilm formation, for example an infection comprising or consisting of 05-10-2012
20110070199ADAPTABLE MODIFIED VIRUS VECTOR TO DELIVER RIBOSOMAL RIBONUCLEIC ACID COMBINED WITH MESSENGER RIBONUCLEIC ACID AS A MEDICAL TREATMENT DEVICE TO MANAGE DIABETES MELLITUS AND OTHER PROTEIN DEFICIENT DIEASES - Diabetes mellitus is a disease of elevated blood glucose, often directly related to a deficiency in insulin production or insulin receptor production. The innovative strategy of treatment described here utilizes modified viruses and virus-like vehicles to act as a transport mechanism to deliver ribosomal RNA molecules along with messenger RNA molecules to target cells in the body. Delivering to the Beta cells in the body the ribosomal RNA needed to assist ribosomes with the construction of insulin or insulin receptors along with messenger RNA will lead to enhanced production of biologically active insulin or insulin receptors by Beta cells as necessary, which will lead to correcting deficiencies in insulin or insulin receptors the result of which will help properly regulate blood glucose levels throughout the body utilizing innate regulatory mechanisms.03-24-2011
20120156174NOVEL BACTERIOPHAGE AND ANTIBACTERIAL COMPOSITION COMPRISING THE SAME - The present invention relates to a novel bacteriophage, more particularly, a bacteriophage that has a specific bactericidal activity against 06-21-2012
20110008294METHODS FOR TREATING CANCER WITH MVA - The invention relates to compositions, kits, and methods for cancer therapy using recombinant MVA viruses encoding a tumor-associated antigen, such as HER-2, particularly in combination with taxanes. The taxanes can be administered prior to, at the same time as, or after the recombinant MVA virus.01-13-2011
20120251503METHODS OF USING CHIMERIC COILED-COIL MOLECULE - The present application discloses a method of treating a disease that is treatable by therapeutic angiogenesis comprising administering to a needy subject an effective amount of a chimeric coiled coil molecule comprising a coiled-coil domain linked to a receptor binding domain of a ligand.10-04-2012
20120251502Human Ebola Virus Species and Compositions and Methods Thereof - Compositions and methods including and related to the Ebola Bundibugyo virus (EboBun) are provided. Compositions are provided that are operable as immunogens to elicit and immune response or protection from EboBun challenge in a subject such as a primate. Inventive methods are directed to detection and treatment of EboBun infection.10-04-2012
20100092430ATTENUATED ONCOLYTIC PARAMYXOVIRUSES ENCODING AVIAN CYTOKINES - The invention refers to a recombinant oncolytic RNA Newcastle Disease Virus for the treatment of a proliferative disease, comprising at least one transgene coding for an avian cytokine, wherein the recombinant oncolytic RNA Newcastle Disease Virus is obtainable from a velogenic or mesogenic oncolytic RNA Newcastle Disease Virus. Virus-mediated expression of the cytokine in the natural host cells leads to a reduced pathogenicity of the virus for avian species. Furthermore the virus genome can encode binding proteins, prodrug-converting enzymes or/and proteases. The selective expression of these molecules in virus-infected tumor cells increases the anti-tumor effect of the virus.04-15-2010
20100247490SIMIAN E ADENOVIRUSES SAdV-39, -25.2, -26, -30, -37, AND -38 - A recombinant vector comprises simian adenovirus SAdV-39, -25.2, -26, -30, -37, and -38 sequences and a heterologous gene under the control of regulatory sequences. A cell line which expresses simian adenovirus SAdV-39, -25.2, -26, -30, -37, and -383 gene(s) is also disclosed. Methods of using the vectors and cell lines are provided.09-30-2010
20120128635METHODS AND COMPOSITIONS FOR TREATING HEMOPHILIA B - Disclosed herein are methods and compositions for insertion of Factor IX (FIX) sequences into the genome of a cell for treating hemophilia B.05-24-2012
20100209395Solenopsis invicta virus08-19-2010
20110182864COMPOSITIONS CONTAINING INCLUSION COMPLEXES - The invention provides a composition containing particulate composite of a polymer and a therapeutic agent. The composition also contains a complexing agent. The polymer interacts with the complexing agent in a host-guest or a guest-host interaction to form an inclusion complex. A therapeutic composition of the invention may be used to deliver the therapeutic agent and to treat various disorders. Both the polymer of the particulate composite and the complexing agent may be used to introduce functionality into the therapeutic composition. The invention also relates to a method of preparing a composition. The method combines a therapeutic agent, a polymer having host or guest functionality, and a complexing agent having guest or host functionality to form the therapeutic composition. The complexing agent forms an inclusion complex with the polymer. The invention also relates to a method of delivering a therapeutic agent. According to the method, a therapeutically effective amount of a therapeutic composition of the invention is administered to a mammal (e.g. person or animal) in recognized need of the therapeutic. Also disclosed are compounds having the formula:07-28-2011
20110182865Method for Prophylaxis and Treatment of Equine Herpesvirus Type 1 Infections - Provided are compositions and methods for treatment and/or prophylaxis of EHV-I infections in horses. The compositions and methods effect treatment and/or prophylaxis of EHV-I infections through RNAi mediated inhibition of EHV-I gB and EHV-I Ori genes, which results in a reduction of the severity of neurological symptoms that are induced by EHV-I infection in horses, and/or a reduction in EHV-I viral shedding in the horses. Included are siRNAs or shRNAs that are designed to target EHV-I gB and EHV-I Ori helicase mRNAs. Also included are vectors encoding such shRNAs.07-28-2011
20110182863ANTI-BACTERIA COMPOSITIONS - The invention relates to anti-bacterial compositions comprising bacteriophage (phage) in sufficiently high concentrations to induce lysis from without in bacteria. Uses of such compositions are disclosed. Phase K and/or P68 are especially preferred.07-28-2011
20100068185METHODS FOR INTRODUCING BACTERIOPHAGE INTO THE INTERIORS OF QUANTITIES OF EDIBLE AGRICULTURAL PRODUCTS AND EDIBLE AGRICULTURAL PRODUCTS WITH PHAGE-CONTAINING PREPARATIONS IN THE INTERIORS THEREOF - Methods for treating foods with bacteriophage include introducing, or incorporating, bacteriophage into the interiors of edible agricultural products, such as ground meats, milled grains, and other ground, cut, or processed edible agricultural products, or solid edible agricultural products. The phage, or a phage-containing preparation of which the phage is a part, may be dispersed throughout the edible agricultural product. Such dispersal may be substantially homogenous. The introduction of phage into the interior of a quantity of an edible agricultural product is useful for controlling bacterial populations in the edible agricultural product.03-18-2010
20120213742VIRUS GROWING IN HYPOXIC CELL OR VIRUS VECTOR EXPRESSING GENE THEREIN - The present invention provides a virus or a viral vector capable of expressing a gene specifically in a cell having replication ability in a hypoxic state such as a cancer stem cell and injuring the cell, and a pharmaceutical composition comprising the same. Specifically, the present invention provides a virus or a viral vector which comprises a gene encoding a fusion protein of an ODD and a protein essentially required for viral proliferation, and a pharmaceutical composition comprising the same.08-23-2012
20120219528Excipients for use in adeno-associated virus pharmaceutical formulations, and pharmaceutical formulations made therewith - Stable pharmaceutical compositions comprising recombinant adeno-associated virus (AAV) virions are described. The compositions provide protection against loss of recombinant AAV vector genomes and transduceability under conditions such as exposure to cycles of freezing and thawing and storage in glass or polypropylene vials. The compositions comprise recombinant AAV virions in combination with one or more dihydric or polyhydric alcohols, and, optionally, a detergent, such as a sorbitan ester. Also described are methods of using the compositions.08-30-2012
20120134964HUMAN MATRIX METALLOPROTEINASE-8 GENE DELIVERY ENHANCES THE ONCOLYTIC ACTIVITY OF A REPLICATING ADENOVIRUS - The present invention discloses a method of treating cancer in a subject. This involves co-administering a replicating virus and a matrix metalloproteinase to the subject under conditions effective to treat cancer. It also relates to a method of enhancing the delivery to and distribution within a tumor mass of therapeutic viruses. This involves co-administering a replicating virus and a matrix metalloproteinase to the tumor mass under conditions effective to enhance the delivery to and distribution within the tumor mass of therapeutic viruses. Another aspect relates to a cancer therapeutic. This involves a replicating virus and a matrix metalloproteinase.05-31-2012
20120237483Oncolytic Virotherapy for Prevention of Tumor Recurrence - Described is a parvovirus for preventing recurrence of a tumor, preferably a malignant brain tumor or pancreas tumor.09-20-2012
20100172877COMPOSITIONS AND METHODS OF USE OF AN ONCOLYTIC VESICULAR STOMATITIS VIRUS - Oncolytic VSV viruses have been developed as a strategy for combating cancer. The present invention includes mutant VSV that have one or more mutations in the nucleic acid sequence encoding the viral genome that increase the oncolytic potential of the virus. Pharmaceutical compositions including oncolytic virus disclosed herein are also provided. Pharmaceutical compositions containing virus and one or more excipients may be for systemic or local administration. Methods of administering an effective amount of the compositions for treating cancer are disclosed. Preferred routes of administration include intratumeral and intravenous injection, and intranasal delivery. Administration of the disclosed compositions containing oncolytic viruses may be coupled with surgical, radiologic, other therapeutic approaches to treatment of cancer. Methods of manufacturing mutant VSV viruses exhibiting desired properties include applying selective pressure, and through directed or random mutagenesis.07-08-2010
20120213741COMMERCIAL SCALE PROCESS FOR PRODUCTION OF PRRSV - The present invention describes an efficient commercial scale production method for the preparation of PRRS virus.08-23-2012
20120177609METHOD FOR USING LIBERATED DORMANT BACTERIOPHASE AND ENVIRONMENTAL STRESS TO REDUCE INFECTIOUS BACTERIA - A method for obtaining bacteriophages by stressing bacteria. The method involves isolating bacteria, propagating the bacteria, exposing the bacteria to at least one environmental stressing agent to induce excision of bacteriophage that are present in the bacterial genome. Multiple or individual environmental stressing agents may be applied. These liberated bacteriophages may be collected for purposes of treating pathogenic infections, protecting plants and agricultural products or general sterilization and sanitation.07-12-2012
20120177608PSEUDOMONAS AERUGINOSA BACTERIOPHAGE(S) AND USES THEREOF - An isolated bacteriophage MR299-2 or NH-4 deposited under NCIMB Deposit Accession Nos. 41729 and 41730, respectively, is described. The phages have lytic activity against 07-12-2012
20100272691Viruses - Herpes Simplex Viruses are disclosed having single-chain antibodies (scFv) embedded in the viral envelope via fusion with glycoprotein D and with glycoprotein H and L.10-28-2010
20090068151Methods and reagents for the enhancement of virus transduction in the bladder epithelium - Agents and methods for enhancing recombinant virus transduction in the bladder epithelium are described. A first method involves contacting the luminal surface of the bladder with a composition comprising a transduction enhancing agent and an oncolytic virus. Alternatively, the luminal surface of the bladder can be contacted first with a pretreatment composition comprising a transduction enhancing agent and, subsequently, with a composition comprising an oncolytic virus. Bladder treatment compositions comprising a transduction enhancing agent and an oncolytic virus are also described.03-12-2009
20090060881Gamma secretase inhibitor for treatment of herpesvirus infection - This invention relates to methods and compositions for the treatment of malignancies associated with gamma-herpesvirus infection. Specifically, the invention relates to the use of gamma-secretase inhibitors to prevent the production of intracellular Notch1 thereby arresting the growth of the infected cells.03-05-2009
20090016993MEDICINAL FORMULATION FOR THE TREATMENT FOR HEPATITIS C - A composition for the treatment of Hepatitis C infection is disclosed. The composition comprises a homogenized mixture of at least one serially diluted and potentized substance, as herein described, selected from: Hepatitis C Genotype 1, Hepatitis C Genotype 2, Hepatitis C Genotype 3, Hepatitis C Genotype 4, Hepatitis C Genotype 5, Hepatitis C Genotype 6 along with a vehicle selected from a group consisting of normal saline, distilled water and ethyl alcohol (90 to 100%). A process for making the composition is also disclosed.01-15-2009
20120230958ONCOLYTIC VACCINIA VIRUS COMBINATION CANCER THERAPY - Embodiments of the invention are directed methods that include a thymidine kinase deficient vaccinia virus. The methods include evaluating a tumor for reperfusion after treatment with vaccinia virus and administering an anti-angiogenic agent if reperfusion is detected.09-13-2012
20080299085High-throughput assay for virus entry and drug screening - The present invention provides a rapid virus entry/binding detection assay. An enzyme such as luciferase was incorporated at the C-terminal end of viral envelope proteins of the HIV Nef protein that would specifically associate with cell membranes to deliver the enzyme into viral particles upon viral assembly. Virus entry/binding can then be assayed by determining the enzymatic activities in infected cells. The assay allows high-throughput non-radioactive detection of virus entry within 30 minutes after virus-cell contact. This assay provides high signal to noise ratio and is useful for screening compounds that affect virus-cell binding and entry. The design also permits packaging of potential therapeutic proteins into functional virus particles and delivering them to specific cellular targets.12-04-2008
20110038840DISINFECTANT COMPOSITION COMPRISING PHAGE - The present invention provides a disinfectant composition including a phage of 02-17-2011
20110044952AMPLIFICATION OF CANCER-SPECIFIC ONCOLYTIC VIRAL INFECTION BY HISTONE DEACETYLASE INHIBITORS - The invention provides methods for treating cancer cells in a host by infecting the cancer cells with one or more strains of oncolytic virus, in conjunction with treating the host with an amount of an HDI that is effective to augment the cancer-cell-specific oncolytic infection.02-24-2011
20120328576DEFINED DOSE THERAPEUTIC PHAGE - The invention provides therapeutic, defined-dose anti-bacterial phage preparations, methods to make such preparations, methods to treat bacterial infections using such preparations and methods to diagnose bacterial infections using such preparations.12-27-2012
20120328577INHIBITION OF BIOFILMS IN PLANTS WITH IMIDAZOLE DERIVATIVES - Disclosure is provided for methods of preventing, removing or inhibiting microbial biofilm formation or microbial infection in a plant or plant part thereof, including applying thereto a treatment effective amount of an active compound as described herein, or an agriculturally acceptable salt thereof. Methods of enhancing a microbicide (e.g., including a copper, antibiotic, bacteriophage, etc.) and/or plant defense activator are also provided, including applying an active compound as described herein. Compositions comprising an active compound as described herein in an agriculturally acceptable carrier are also provided, and in some embodiments the compositions further include a microbicide (e.g., including copper, antibiotic, bacteriophage, etc.) and/or plant defense activator.12-27-2012
20120328575Modified Oncolytic Viruses - The present invention provides an isolated selected Picornavirus capable of lytically infecting or inducing apoptosis in a cell substantially in the absence of intercellular adhesion molecule-1 (ICAM-1), and methods for treating subjects.12-27-2012
20100215621Recombinant Adenoviruses Capable Of Regulating Angiogenesis - The present invention relates to a recombinant adenovirus capable of regulating angiogenesis, which comprises (a) an adenoviral ITR (inverted terminal repeat) nucleotide sequence; and (b) a transcription regulatory sequence for a VEGF-A (vascular endothelial growth factor-A) gene comprising (i) a nucleotide sequence encoding a DNA binding domain comprising a zinc finger domain to bind to a site in a VEGF-A promoter sequence as set forth in nucleotides 1-2362 of SEQ ID NO:1, and (ii) a transcription activation domain or a transcription inhibitory domain linked to the nucleotide sequence encoding the DNA binding domain; and a pharmaceutical composition comprising the recombinant adenovirus.08-26-2010
20120100109Method for increasing the replication of oncolytic HSVs in highly resistant tumor cells using mTOR pathway and PI3K inhibitors - The present invention is directed to the administration of an HSV derived oncolytic virus and a PI3K/AKT/mTOR pathway inhibitor to treat various types of resistant tumors. Therapy-resistant tumor formation is one of the main causes for treatment failure in the clinic. The treatment methods and compositions disclosed herein sensitize resistant tumors to the treatment of herpes simplex virus (HSV)-based oncolytic virotherapy. Pre or co-treatment of resistant tumor cells with the mTOR inhibitor, rapamycin, or certain PI3K inhibitors, such as LY294002, can efficiently sensitize the tumors to HSV derived oncolytic viruses, whereby the replication and spread of the viruses are dramatically enhanced.04-26-2012
20120288479Cross-Linked Polymer Based Hydrogel Material Compositions, Methods and Applications - A hydrogel material composition includes: (1) an alginate (or other cross-linking polymer) material; (2) an optional α-hydroxy carboxylate material; and (3) an iron cation material. The hydrogel material composition with or without the α-hydroxy-carboxylate material may be used in a photolithographic imaging application or a photorelease application within the context of a photoirradiation induced reduction/oxidation reaction of an iron (III) cation material to form an iron (II) cation material.11-15-2012
20100203019Podoviriedae bacteriophage having killing activity specific to staphylococcus aureus - The present invention relates to a novel bacteriophage, more precisely a Podoviridae bacteriophage having killing activity specific to 08-12-2010
20130011369Method for Prevention and Treatment of Salmonella Infection - The present invention relates to a composition comprising bacteriophage SP-1, the bacteriophage capable of destroying 01-10-2013
20130011370Uniform Field Magnetization and Targeting of Therapeutic Formulations - Systems and methods for magnetic targeting of therapeutic particles are provided. Therapeutic particles comprise one or more magnetic or magnetizable materials and at least one therapeutic agent. Therapeutic particles are specifically targeted using uniform magnetic fields capable of magnetizing magnetizable materials, and can be targeted to particular locations in the body, or can be targeted for capture, containment, and removal. Also provided are bioresorbable nanoparticles prepared without the use of organic solvents, and methods for therapeutically using such bioresorbable nanoparticles.01-10-2013
20110158953TUMOR SUPPRESSION THROUGH PLEXIN C1 - Disclosed are compositions and methods relating to Plexin C1 and diagnosing, treating, and evaluating treatment for cancer.06-30-2011
20110158952COMPOSITIONS AND METHODS FOR TREATING HUMAN PAPILLOMAVIRUS-MEDIATED DISEASE - The invention includes methods of treating an HPV-mediated disease by administration to an individual of a pharmaceutical composition comprising a nucleic acid that encodes a polypeptide comprising an epitope of a naturally occurring HPV protein. The methods include the selection of individuals for treatment with the composition according to a the age of the recipient, as well as the use of the composition to elicit a cross-reactive anti-HPV immune response.06-30-2011
20130022579BACTERIOPHAGE AND ANTIBACTERIAL COMPOSITION COMPRISING THE SAME - The present invention relates to a novel bacteriophage, more particularly, a bacteriophage that has a specific bactericidal activity against 01-24-2013
20080241105Method and reagents for the enhancement of virus transduction in the bladder epithelium - Agents and methods for enhancing recombinant virus transduction in the bladder epithelium are described. A first method involves contacting the luminal surface of the bladder with a composition comprising a transduction enhancing agent and an oncolytic virus. Alternatively, the luminal surface of the bladder can be contacted first with a pretreatment composition comprising a transduction enhancing agent and, subsequently, with a composition comprising an oncolytic virus. Bladder treatment compositions comprising a transduction enhancing agent and an oncolytic virus are also described.10-02-2008
20110274661Attentuated Herpesvirus Encoding a Mek Pathway Polypeptide - The disclosure provides materials and methods for the treatment of cells exhibiting a cell proliferative disorder with a herpes simplex virus having a deficiency in the expression of active ICP34.5 and comprising an expression control element effective in modulating at least one component of the MEK pathway to ensure that infected cells are MEK+. Cell proliferative diseases, disorders or conditions, such as cancers, rheumatoid arthritis and macular degeneration, are amenable to treatment using these HSVs. Further provided are methods for preventing such cell proliferative disorders by administering the HSVs as well as methods for ameliorating a symptom associated with a cell proliferative disorder by administering such HSVs.11-10-2011
20130177533METHOD FOR TREATING INFLAMMATION ASSOCIATED WITH AMYLOID DEPOSITS AND BRAIN INFLAMMATION INVOLVING ACTIVATED MICROGLIA - Filamentous bacteriophage which does not display an antibody or a non-filamentous bacteriophage antigen on its surface is used to inhibit or treat brain inflammation associated with amyloid deposits and/or involving activated microglia, to inhibit the formation of amyloid deposits, and to disaggregate pre-formed amyloid deposits.07-11-2013
20130177534PLANT PROTECTION AGENT COMPRISING INSECT-PATHOGENIC VIRUSES, IN PARTICULAR BACULOVIRUSES, AND CELLULOSE SULFATE - The present invention relates to a crop protection agent containing insect-pathogenic viruses, in particular baculoviruses, and cellulose sulfate and/or derivatives thereof.07-11-2013
20130129685Stabilisation of Viral Particles - A method for preserving viral particles comprising: (a) providing an aqueous solution of (i) viral particles, (ii) optionally one or more sugars, and (iii) a compound of formula (I) or a physiologically acceptable salt or ester thereof and/or a compound of formula (II) or a physiologically acceptable salt or ester thereof; and (b) drying the solution to form a composition incorporating said viral particles.05-23-2013
20110217268THERAPY OR PROPHYLAXIS OF KLEBSIELLA PNEUMONIAE INFECTIONS WITH A LYTIC BACTERIOPHAGE SPECIFICALLY AGAINST THE K. PNEUMONIAE - A therapy or prophylaxis of 09-08-2011
20080199436Polypeptides Having Brain-Localizing Activity and Uses Thereof - DNAs encoding polypeptides comprising random amino acid sequences were synthesized, and incorporated into a phage library. The phage library produced was used to screen for polypeptides having brain-localizing activity. As a result, several polypeptides having brain-localizing activity were obtained. These polypeptides comprise common sequences, and amino acid motif sequences involved in brain-localizing activity were successfully identified.08-21-2008
20110243896ANTI-VIRAL PROTECTION WITH VIRUSES CONTAINING DEFECTIVE GENOME SEGMENTS - The invention relates to virology and the prevention and/or treatment of viral infection and disease in animals, including birds and humans. The invention relates to the field of antiviral treatments. The invention further relates to methods of stimulating innate immunity and natural interferon production in humans or animals and in component parts of humans or animals, including cells and tissues. The invention also relates to the field of defective interfering (DI) viruses, including cloned DI viruses.10-06-2011
20090180991METHOD FOR TREATING INFLAMMATION ASSOCIATED WITH AMYLOID DEPOSITS AND BRAIN INFLAMMATION INVOLVING ACTIVATED MICROGLIA - Filamentous bacteriophage which does not display an antibody or a non-filamentous bacteriophage antigen on its surface is used to inhibit or treat brain inflammation associated with amyloid deposits and/or involving activated microglia, to inhibit the formation of amyloid deposits, and to disaggregate pre-formed amyloid deposits.07-16-2009
20110311490Recombinant Bacteriophages Useful for Tissue Engineering - The invention provides for a composition comprising a genetically engineered bacteriophage capable of guiding cell growth and polarization via signaling peptides and directionally aligned structures. The invention provides for modified bacteriophage and its uses thereof. The present invention also provides for genetically engineered phage capable of guiding cell growth, migration and/or alignment, providing essential biological effects including proliferation and/or differentiation, which can be performed by expressing specific biological motifs, such as the amino acid sequences RGD, IKVAV, DGEA and HPQ, on their coat proteins, on which functional DNA, proteins and cells can be conjugated and/or fixed thereon.12-22-2011
20130189229METHOD FOR PROTECTING PLANTS USING INSECT-PATHOGENIC VIRUSES AND CELLULOSE SULFATE - The invention relates to a method of protecting plants, in which plant protection agents containing insect-pathogenic viruses and cellulose sulfate are applied onto the plants.07-25-2013
20120093780PROCESS FOR PRODUCING POXVIRUSES AND POXVIRUS COMPOSITIONS - The present invention relates to compositions and pharmaceutical compositions comprising poxviruses and more particularly extracellular enveloped viruses. The present invention also relates to a process for producing poxviruses and poxviruses obtained thereof. Moreover, the present invention also relates to the use of said poxvirus and said composition for the preparation of a medicament.04-19-2012
20130209413USE OF PARVOVIRUS FOR ELIMINATING CANCER STEM CELLS (CSCs) - Described is the use of a parvovirus, preferably H-1PV, for the therapeutical elimination of cancer stem cells (CSCs), preferably neuroblastoma stem cells and glioblastoma stem cells.08-15-2013

Patent applications in class Virus or bacteriophage